2026 Q2 -tulosraportti
9 päivää sitten
‧48 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 22.7. | ||
2026 Q1 -tulosraportti 23.4. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·12 t sittenClassic Bull Trap and distribution (my opinion) After a bull trap (my opinion) above 40,50, see my previous posts, short selling has increased again along with likely some distribution. We have already seen large selling volumes, among others from insiders. Short positions have also been bought back somewhat at higher price levels, and they therefore have somewhat less risk of contributing to increased selling pressure in the market. Above the current price, there is resistance from investors holding loss positions. Those who bought the stock after SEB's recommendation are now at a loss. Short sellers also know that investors with certificates or high leverage are often more vulnerable. Their positions can therefore be relatively easily forced into selling, which can further benefit the short sellers' strategy. My opinion and not advice.
·18 t sitten · MuokattuThere is ONE thing - and ONLY one - that determines whether this stock loses 80% or 3-5x in the next 6-12 months - and that is the decision from the FDA which is currently set for December 2026. And no one - absolutely NO ONE - has any idea what the FDA will decide. So it makes no sense to interpret this insignificant announcement. Let's say it's only 50% (we don't know that) he sells for 18 million - perhaps with a profit of 9 million (we don't know that either) - then he has boosted his personal finances with a decent amount - and is still part of the potential for an approval. If that's how it is, I could have done the same - I have actually also reduced my exposure a bit during the latest increase
No one knows the answer regarding fda or anything. But I understand well why one chooses to sell off at that price. Hansa will in no way 3-5 times in the next 6-12 months, maybe there can be an increase to around 50-60kr with an approved fda. But it's all about can it be sold in usa? After the sales figures of the last 5 years, it's not exactly something that confirms Hansa's own fantasy figures of 2 billion dollars in sales in usa. So we will see the same trading pattern: upon approval, it will rise sharply and then fall. As long as there is no control over sales or costs. They have supposedly sold the rights in eu for 1 billion, what would make the rights in usa worth 15 billion?
·20 t sittenI understand that news like this can create concern, especially when the share price has already been weak. But I still think it's important not to draw too far-reaching conclusions from a single insider transaction. It concerns a close associate of a board member, and we don't know why the sale was made. It could just as easily be about personal finances, taxes, or a reallocation of capital as it is about the view on the company. For me, the company's development is still what's important – how sales develop, how studies progress, and what announcements are made going forward. That's what ultimately determines the value, not a single transaction. I therefore do not intend to let this news alone influence my decision. The stock market often tests patience, and sometimes it's about distinguishing between noise and what actually changes the case. We'll see what upcoming reports and news show before we draw any major conclusions. Regards, Janne
·21 t sittenWhat a damn bad signal to send to the market with that big sale, he could have done it gradually instead, that idiot should have a tough time with this one with them not getting control of their costs.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
9 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·12 t sittenClassic Bull Trap and distribution (my opinion) After a bull trap (my opinion) above 40,50, see my previous posts, short selling has increased again along with likely some distribution. We have already seen large selling volumes, among others from insiders. Short positions have also been bought back somewhat at higher price levels, and they therefore have somewhat less risk of contributing to increased selling pressure in the market. Above the current price, there is resistance from investors holding loss positions. Those who bought the stock after SEB's recommendation are now at a loss. Short sellers also know that investors with certificates or high leverage are often more vulnerable. Their positions can therefore be relatively easily forced into selling, which can further benefit the short sellers' strategy. My opinion and not advice.
- ·18 t sitten · MuokattuThere is ONE thing - and ONLY one - that determines whether this stock loses 80% or 3-5x in the next 6-12 months - and that is the decision from the FDA which is currently set for December 2026. And no one - absolutely NO ONE - has any idea what the FDA will decide. So it makes no sense to interpret this insignificant announcement. Let's say it's only 50% (we don't know that) he sells for 18 million - perhaps with a profit of 9 million (we don't know that either) - then he has boosted his personal finances with a decent amount - and is still part of the potential for an approval. If that's how it is, I could have done the same - I have actually also reduced my exposure a bit during the latest increaseNo one knows the answer regarding fda or anything. But I understand well why one chooses to sell off at that price. Hansa will in no way 3-5 times in the next 6-12 months, maybe there can be an increase to around 50-60kr with an approved fda. But it's all about can it be sold in usa? After the sales figures of the last 5 years, it's not exactly something that confirms Hansa's own fantasy figures of 2 billion dollars in sales in usa. So we will see the same trading pattern: upon approval, it will rise sharply and then fall. As long as there is no control over sales or costs. They have supposedly sold the rights in eu for 1 billion, what would make the rights in usa worth 15 billion?
- ·20 t sittenI understand that news like this can create concern, especially when the share price has already been weak. But I still think it's important not to draw too far-reaching conclusions from a single insider transaction. It concerns a close associate of a board member, and we don't know why the sale was made. It could just as easily be about personal finances, taxes, or a reallocation of capital as it is about the view on the company. For me, the company's development is still what's important – how sales develop, how studies progress, and what announcements are made going forward. That's what ultimately determines the value, not a single transaction. I therefore do not intend to let this news alone influence my decision. The stock market often tests patience, and sometimes it's about distinguishing between noise and what actually changes the case. We'll see what upcoming reports and news show before we draw any major conclusions. Regards, Janne
- ·21 t sittenWhat a damn bad signal to send to the market with that big sale, he could have done it gradually instead, that idiot should have a tough time with this one with them not getting control of their costs.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 22.7. | ||
2026 Q1 -tulosraportti 23.4. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 |
2026 Q2 -tulosraportti
9 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 22.7. | ||
2026 Q1 -tulosraportti 23.4. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·12 t sittenClassic Bull Trap and distribution (my opinion) After a bull trap (my opinion) above 40,50, see my previous posts, short selling has increased again along with likely some distribution. We have already seen large selling volumes, among others from insiders. Short positions have also been bought back somewhat at higher price levels, and they therefore have somewhat less risk of contributing to increased selling pressure in the market. Above the current price, there is resistance from investors holding loss positions. Those who bought the stock after SEB's recommendation are now at a loss. Short sellers also know that investors with certificates or high leverage are often more vulnerable. Their positions can therefore be relatively easily forced into selling, which can further benefit the short sellers' strategy. My opinion and not advice.
- ·18 t sitten · MuokattuThere is ONE thing - and ONLY one - that determines whether this stock loses 80% or 3-5x in the next 6-12 months - and that is the decision from the FDA which is currently set for December 2026. And no one - absolutely NO ONE - has any idea what the FDA will decide. So it makes no sense to interpret this insignificant announcement. Let's say it's only 50% (we don't know that) he sells for 18 million - perhaps with a profit of 9 million (we don't know that either) - then he has boosted his personal finances with a decent amount - and is still part of the potential for an approval. If that's how it is, I could have done the same - I have actually also reduced my exposure a bit during the latest increaseNo one knows the answer regarding fda or anything. But I understand well why one chooses to sell off at that price. Hansa will in no way 3-5 times in the next 6-12 months, maybe there can be an increase to around 50-60kr with an approved fda. But it's all about can it be sold in usa? After the sales figures of the last 5 years, it's not exactly something that confirms Hansa's own fantasy figures of 2 billion dollars in sales in usa. So we will see the same trading pattern: upon approval, it will rise sharply and then fall. As long as there is no control over sales or costs. They have supposedly sold the rights in eu for 1 billion, what would make the rights in usa worth 15 billion?
- ·20 t sittenI understand that news like this can create concern, especially when the share price has already been weak. But I still think it's important not to draw too far-reaching conclusions from a single insider transaction. It concerns a close associate of a board member, and we don't know why the sale was made. It could just as easily be about personal finances, taxes, or a reallocation of capital as it is about the view on the company. For me, the company's development is still what's important – how sales develop, how studies progress, and what announcements are made going forward. That's what ultimately determines the value, not a single transaction. I therefore do not intend to let this news alone influence my decision. The stock market often tests patience, and sometimes it's about distinguishing between noise and what actually changes the case. We'll see what upcoming reports and news show before we draw any major conclusions. Regards, Janne
- ·21 t sittenWhat a damn bad signal to send to the market with that big sale, he could have done it gradually instead, that idiot should have a tough time with this one with them not getting control of their costs.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt